AIO INTEGA trial evaluated the efficacy of ipilimumab vs. FOLFOX in combination with nivolumab and trastuzumab in previously untreated ERBB2-positive esophagogastric adenocarcinoma (EGA), and the FOLFOX group showed better survival data with an ORR of 63% and a 1-year OS rate of 70%, indicating that at the current stage, chemotherapy removal is not an advisable choice (15). This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.